Telehealth offers an opportunity to address limited access to early medical abortion during COVID‐19 and beyond
Access to early medical abortion (EMA), using mifepristone followed by misoprostol to end an early pregnancy, remains a challenge in Australia, especially for women from vulnerable groups and those living in rural and regional areas.1 Low numbers of general practitioner providers, lack of peer networks to support the establishment and ongoing provision of EMA services, and stigma are real barriers as is a broader lack of knowledge regarding medical abortion among health professionals.2,3 Many women are also unaware of the availability of EMA and the current gestational limit of 63 days.4 They also face difficulties navigating the health system to find an EMA provider, particularly when they encounter conscientious objections.4,5 Women can also face other barriers such as needing to travel to access services, take time off work or find childcare, and many need to source financial support to meet the costs.5
- 1. Mazza D, Burton G, Wilson S, et al. Medical abortion. Aust J Gen Pract 2020; 49: 324–330.
- 2. Subasinghe AK, Deb S, Mazza D. Primary care providers’ knowledge, attitudes and practices of medical abortion: a systematic review. BMJ Sex Reprod Health 2019; https://doi.org/10.1136/bmjsrh-2019-200487 [Epub ahead of print].
- 3. Deb S, Subasinghe AK, Mazza D. Providing medical abortion in general practice: General practitioner insights and tips for future providers. Aust J Gen Pract 2020; 49: 331–337.
- 4. Newton D, Bayly C, McNamee K, et al. How do women seeking abortion choose between surgical and medical abortion? Perspectives from abortion service providers. Aust N Z J Obstet Gynaecol 2016; 56: 523–529.
- 5. LaRoche KJ, Wynn LL, Foster AM. “We've got rights and yet we don't have access”: Exploring patient experiences accessing medication abortion in Australia. Contraception 2020; 101: 256–260.
- 6. Marie Stopes Australia. Situational report: sexual and reproductive health rights in Australia. A request for collaboration and action to maintain contraceptive and abortion care throughout the SARS‐CoV-2/COVID‐19 pandemic. https://resources.mariestopes.org.au/SRHRinAustralia.pdf (viewed June 2020).
- 7. Ireland S, Belton S, Doran F. “I didn't feel judged”: exploring women's access to telemedicine abortion in rural Australia. J Prim Health Care 2020; 12: 49–56.
- 8. Hyland P, Raymond EG, Chong E. A direct‐to-patient telemedicine abortion service in Australia: Retrospective analysis of the first 18 months. Aust N Z J Obstet Gynaecol 2018; 58: 335–340.
- 9. Endler M, Lavelanet A, Cleeve A, et al. Telemedicine for medical abortion: a systematic review. BJOG 2019; 126: 1094–1102.
- 10. Aiken ARA, Digol I, Trussell J, Gomperts R. Self reported outcomes and adverse events after medical abortion through online telemedicine: population based study in the Republic of Ireland and Northern Ireland. BMJ 2017; 357: j2011.
- 11. Kidd M. Australia's primary care COVID‐19 response. Aust J Gen Pract 2020; https://doi.org/10.31128/ajgp-covid-02 [Epub ahead of print].
- 12. Australian Government, Department of Health. Telehealth changes improve remote Australians’ access to a doctor 2019 [media release]. 29 Oct 2019. https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/telehealth-changes-improve-remote-australians-access-to-a-doctor (viewed June 2020).
- 13. Australian Government, Department of Health. Continuous care with telehealth stage seven [media release]. 10 July 2020. https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/continuous-care-with-telehealth-stage-seven (viewed July 2020).
- 14. Women's Sexual and Reproductive Health COVID‐19 Coalition. Evidence‐based practice and policy recommendations regarding early medical abortion: a consensus statement. SPHERE NHMRC Centre of Research Excellence in Women's Sexual and Reproductive Health in Primary Care, 2020. https://3fe3eaf7-296b-470f-809a-f8eebaec315a.filesusr.com/ugd/410f2f_accfc0aeceaf4e7cb5cb0948a1248f27.pdf (viewed June 2020).
- 15. RADAR. Mifepristone and misoprostol (MS‐2 Step) composite pack: use extended to 63 days’ gestation. Sydney: NPS MedicineWise, 2015. www.nps.org.au/radar/articles/mifepristone-and-misoprostol-ms-2-step-composite-pack-use-extended-to-63-days-gestation (viewed June 2020).
- 16. Kapp N, Eckersberger E, Lavelanet A, Rodriguez MI. Medical abortion in the late first trimester: a systematic review. Contraception 2019; 99: 77–86.
- 17. Costescu D, Guilbert E, Wagner MS, et al. Induced abortion: updated guidance during pandemics and periods of social disruption. Society of Obstetricians and Gynaecologists of Canada, 2020. https://sogc.org/common/Uploaded%20files/Induced%20Abortion%20-%20Pandemic%20Guidance%20-%20FINAL.PDF (viewed June 2020).
- 18. US Food and Drug Administration. Mifeprex (mifepristone) information. FDA, 2018. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/mifeprex-mifepristone-information (viewed June 2020).
- 19. Royal College of Obstetricians and Gynaecologists. Coronavirus (COVID‐19) infection and abortion care. Information for healthcare professionals. London: RCOG, 2020. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/coronavirus-abortion/ (viewed June 2020).
- 20. Raymond EG, Grossman D, Mark A, et al. No‐test medication abortion: a sample protocol for increasing access during a pandemic and beyond. Contraception 2020; 101: 361–366.
- 21. Royal Australian and New Zealand College of Obstetricians and Gynaecologists. COVID‐19: anti D and abortion. RANZCOG, 2020. https://ranzcog.edu.au/news/covid-19-anti-d-and-abortion (viewed May 2020).
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.